logo
dupixent_product
EoE is a chronic inflammatory disease that damages the esophagus and prevents it from working properly. The results seen with Dupixent in adults and children with EoE demonstrate that IL-4 and IL-13 are key and central drivers of the type 2 inflammation underlying this disease

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 ...

Dupixent led to significant improvements in the primary efficacy measure for higher (n=37) and lower (n=31) dose groups at 16 weeks in the randomized, placebo-controlled Phase 3 trial. Among children treated with Dupixent, 68% of children on higher dose and 58% of patients on lower dose achieved the primary endpoint of significant histological disease remission, compared to 3% for placebo (both p<0.0001)

By Sanofi - Aventis Groupe
Published - Oct 11, 2022, 01:16 AM ET
Last Updated - Jul 17, 2024, 01:15 AM EDT

Dupixent®(dupilumab)late-breakingPhase 3 data presented at UEG Week 2022 showed significanthistological remissionof eosinophilic esophagitis(EoE)in children 1 to 11 yearsold

  • 68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
  • First and only Phase 3 trial to show positive results in this patient population; currently no approved treatments are specifically indicated for children under 12 years of age with EoE
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024